Roots Analysis has done a detailed study on “Global Regulatory T-Cell (Tregs) Therapies Market”, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
Given the various benefits offered, including high target specificity, customization potential and ability to generate immunological memory, regulatory T-cell (Treg) therapies have garnered significant attention among key industry stakeholders for the treatment of various oncological and non-oncological disease indications. Tregs have been observed to be capable of acting through more than one mechanism of suppression, depending on tissue site, type of cell and activation status of the target cell. In the future, high demand for personalized therapeutics with limited toxicity and high efficiency are likely to drive the growth of the Treg cell therapies market.
The USD 442 million (by 2035) financial opportunity within the regulatory T-Cell therapies market has been analyzed across the following segments:
- Type of Product
- Tregs
- Interleukins
- Small molecules
- Target Indication
- Crohn’s Disease
- Bipolar Disorder
- Allergic Rhinoconjunctivitis
- COVID 19
- Diabetes Mellitus
- Systemic Lupus Erythematosus
- Alzheimer’s Disease
- Graft Vs Host Disease
- Key Geographical Regions
- North America
- Europe
- Asia Pacific
The Regulatory T-Cell Therapies Market, 2021 – 2035 report features the following companies, which we identified to be key players in this domain:
- Abata Therapeutics
- Cellenkos
- Coya Therapeutics
- ILTOO Pharma
- NEKTAR
- Roche
- Sonoma Biotherapeutics
- TeraImmune
- TRACT Therapeutics
Table of Contents
- Preface
2. Executive Summary
- Introduction
- Current Market Landscape
- Therapy Profiles
- Clinical Trial Analysis
- Partnerships and Collaborations
- Funding and Investment Analysis
- Porter’s Five Analysis
- Company Profiles
- Market Sizing and Opportunity Analysis
- Conclusion
- Executive Insights
- Appendices
One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities associated with Treg cell therapies, over the coming decade. The report also includes likely sales forecasts of Treg cell therapies that are in the mid to late stages of development.
For more information, please visit https://www.rootsanalysis.com/reports/regulatory-t-cell-therapies-market.html
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
